TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abbisko Cayman Limited ( (HK:2256) ) just unveiled an update.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has completed the first patient enrollment for an observational study aimed at treating children with Achondroplasia (ACH). This study will gather baseline data for ABSK061, a selective small molecule inhibitor of FGFR2/3, which could potentially offer a new treatment option for ACH, a rare disorder with no specific medications currently available in China. The successful enrollment marks a significant step in Abbisko’s efforts to address this unmet medical need and could enhance its positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company. It is dedicated to discovering and developing innovative medicines to address unmet medical needs in China and globally, with a focus on precision oncology and immuno-oncology.
Average Trading Volume: 5,596,496
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.06B
For an in-depth examination of 2256 stock, go to TipRanks’ Overview page.